Oxyfunctionalized metabolites 48
Introduction 50
Next to chemical processes, biotechnology routes can play a significant role for the access 51 to pharmaceutically active substances and their metabolites. Metabolites and degradation 52 intermediates can have major environmental implications, which can lead to unwanted side 53 reactions in nature and mammalians. Due to the fact that numerous drug metabolites are 54 detected in higher amounts in different habitats, thus detailed environmental and 55 toxicological studies are necessary. These findings induced that the FDA (Food and Drug 56 Administration) issued guidelines for metabolites in drug testing, setting a limit of 10% in 57 8 spectrometry proteomics data have been deposited to the ProteomeXchange Consortium 155 via the PRIDE (30) partner repository with the dataset identifier PXD009664 and 156
10.6019/PXD009664. 157 158

Preparative biotransformations 159
The filamentous fungi applied in this work were cultured in PEG broth, in which a better 160 growth could be achieved in comparison to sabouraud medium. On PEG-agar, the hyphae 161 were transferred once a month and incubated at 27°C for several days (M. hiemalis: 3 days, 162
B. bassiana: 4 days, C. nebularis: 5 days). B. bassiana used in this work was modified by 163
UV radiation to allow yeast-like growth in liquid culture (31). 50 mL of PEG broth was 164 once inoculated with a loop tip, whereas M. hiemalis and C. nebularis were inoculated 165 several times with hyphae to slightly disperse and therefore minimize lumpy mycelial 166 growth. The fungi were cultured for 4 days at 27°C and 180 rpm and then transferred to 167 50 -400 ml main cultures which were inoculated with 1/75 volume (B. bassiana) or with 168 the filtered mycelia (M. hiemalis and C. nebularis) of the preculture. After 24 h of 169 incubation, the biotransformations were started with 1 g L -1 substrate (50 g L -1 stock 170 solution in DMSO) or in the case of diclofenac (1) with 0.6 g L -1 for 72 h or 144 h, 171 respectively. At regular intervals, 500 μL samples were taken, centrifuged and the 172 supernatant was used for analysis by GC-FID, HPLC-DAD or LC-MS. The 173 biotransformations were carried out in biological duplicates starting from different agar 174
plates. 175 Diclofenac (1) and its metabolites were analyzed by HPLC and LC-MS as described 179 elsewhere (21) . 180
181
GC analytic 182
Naproxen (6), ibuprofen (8) and mefenamic acid (12) were analyzed by gas 183 chromatography. For this purpose, the samples (500 μL) were centrifuged and 250 µL of 184 the supernatant initially acidified by 10 μL HCl prior extraction with the same volume of 185 MTBE. The organic phase was then evaporated on a Genevac EZ-2 Plus Evaporator 186 (Ipswich, UK) and resuspended in a mix of 50% MTBE and 50% BSTFA + TCMS (99: 1). 187
The derivatization of the samples (150 μL) was carried out in GC vials at 70°C for 30 min. 188 GC analysis was performed on a Shimadzu GC-2010 equipped with an AOC-20i 189 autoinjector (Shimadzu, Nakagyo-ku, Japan). The samples were injected with a split of 20 190
(1 µL injection volume, injector temperature 250°C, carrier gas H2, 30 cm s -1 ) and 191 separated by a DB-5 column (30 m x 0.25 mm x 0.25 µm, Agilent Technologies, Santa 192 Clara, California, USA). The analytes were detected by a flame ionization detector (FID, 193 detector temperature 330°C). For 6 and 12 the column temperature was maintained at 194 150°C for 1 min, increased to 280°C at a rate of 10°C min -1 and held for 1 min, raised to 195 320°C at a rate of 65°C min -1 and held for 3 min. For 8 the column temperature was 196 maintained at 90°C for 1 min, increased to 280°C at a rate of 12°C min -1 and held for 1 min, 197 raised to 320°C at a rate of 65°C min -1 and held for 3 min. 198
For initial product identification, the samples were run on GC-2010 GC-MS system 199 equipped with Shimadzu GCMS-QP2010 detector and AOC-5000 autoinjector (Shimadzu, 200 Nakagyo-ku, Japan) and helium as carrier gas (linear velocity 30 
Product purification and identification 208
For product purification, the supernatant of the duplicates (2 x 50 mL or 2 x 400 mL) from 209 preparative biotransformations were extracted twice with the identical volume of MTBE. 210
In the case of biotransformations with substrate 6, 8 and 12, the supernatant was 211 additionally acidified with HCl and afterwards extracted with MTBE. The organic phases 212 were combined, evaporated to dryness and the residues were dissolved in 10 mL of 213 acetonitrile and stored at 4°C for further use. The batches were finally purified by reverse 214 phase semi-preparative HPLC on an Agilent 1200 System (St. Clara, California, USA) 215 equipped with a G1311A quaternary pump, a HIP AS G1367B autosampler (1200 μL 216 loop), a G1315D DAD detector and an analytical G1364C fraction collector. The 217 separation of the analytes (injection volume: 1000 µL) was ensured using a Trentec 218 
NMR measurements 232
For the characterization of the purified products, NMR spectroscopy was used.
1 H-, 233 1 H-COSY-and 1 H-NMR (500 MHz, (CD3)2SO): δ (ppm) 2.11 (s, 3H, 287 C-8'), 4.53 (s, 2H, C-7'), 6.68 -6.73 (m, 2H, C-2 and C-4), 7.18 -7.25 (m, 3H, C-4', 5' 288 and 6'), 7.31 (t, 1H, J = 7.5 Hz, C-3), 7.89 (d, 1H, J = 7.5 Hz, C-5). 
Results and Discussion 301
Identification of microbial biocatalysts for NSAID oxyfunctionalizations 302
In addition to the already published organism Beauveria bassiana, which is able to perform 303 one of the most effective hydroxylation processes in biocatalysis, the production of (R)-2-304 (4-hydroxyphenoxy)propionic acid and a variety of other hydroxylation reactions (31, 32), 305 we identified two other filamentous fungi as further novel NSAID accepting biocatalysts. 306
One of these strains was isolated from soil samples close to Ludwigshafen (Germany) 307 during previous diclofenac (1) degradation experiments (33). The third filamentous fungus 308 was isolated by coincident as a contamination strain out of a 5-hydroxydiclofenac (3) 309 standard, diluted in M9 minimal medium, after 1.5 years of aerobic incubation. Both fungi 310 were assigned by the universal biomarkers LSU (28S nuclear ribosomal large subunitS1 organism Clitocybe nebularis (confirmed by LSU and ITS biomarkers). For the other 314 organism, the LSU biomarker found a > 98% similarity with the S1 organism 315
Mucor hiemalis. 316
Biotransformations with diclofenac 317
The fungi were cultivated in 400 mL PGE broth and the biotransformations were done in 318 duplicates with a starting concentration of 0.6 g L -1 diclofenac (1). The reaction was 319 monitored over time by HPLC-DAD and stopped after 144 h (Figure 1 ). All products were 320 purified by semi-preparative HPLC for further detailed structure identification by 1 H and 321 13 C NMR. Similar to the distribution of products in humans, the 4'-position (2) was 322 favoured in the biotransformations with the fungi, which was also observed with P450s 323 and microorganisms in previous studies (Scheme 1, Table 1 ). In comparison to 324 C. nebularis which is able to catalyze a mixture of the metabolites 4'-hydroxydiclofenac 325 (2, 60%), 5-hydroxydiclofenac (3, 30%) and the corresponding quinoneimine (4, 10%) 326 with 50.6% isolated yield, M. hiemalis selectively oxyfunctionalized diclofenac (1) 327 yielding 61.7% of 4'-hydroxydiclofenac (2) after purification. High isolated yields of 328 55.3% were additionally achieved using B. bassiana. Next to the major product 329 4'-hydroxydiclofenac (2, 90%), a 3',4'-dihydroxydiclofenac (5) metabolite was identified 330 that has not been characterized and published yet. In studies concerning the fungi 331
Epicoccum nigrum and Cunninghamella elegans, preparative biotransformations were 332 performed resulting in product titers of 16 and 57 mg L -1 , respectively (34, 35) . In contrast, 333 the filamentous fungi identified in the present work were able to obtain significantly higher 334 values comparable with biotransformations using P450 RhF and P450 BM3 (Table 1) .
A common question that is often raised as a negative element for the use of microbial cell 337 factories is which enzymes are involved in the detected biotransformation. In this respect, 338 we aimed to identify 450s, which are responsible for the oxyfunctionalization of diclofenac 339
(1) and (R)-2-phenoxypropionic acid in B. bassiana using omics studies. As a proof of 340 concept, we analyzed biotransformation samples whether we can identify differences by a 341 proteome analysis depending on the substrate. Therefore, samples of biotransformations 342 with the corresponding substrates and glucose as negative control were processed to obtain 343 the organisms proteome. By applying the proteome analysis clear evidence of P450s 344 (implied by the number of detected and assigned fragments) which were upregulated with 345 the specific substrates, were achieved drastically reducing the high number of 83 putative 346 P450s in B. bassiana (36). With diclofenac (1) as substrate two P450s, CYP548A5 and 347 CYP51F1, were exclusively expressed compared to the samples exposed with the other 348 substrates (Table 2 ). In case of (R)-2-phenoxypropionic acid as substrate, CYP52A10 349 seems to be strongly upregulated while CYP684A2 was induced exclusively. In 350 eukaryotes, only one bifunctional NADPH-reductase serves as electron delivering partner 351 that was also found in all samples. In this work, the proteome analysis has thus proved to 352 be a targeted method for identifying involved proteins in eukaryotes that can subsequently 353 lead to valuable new heterologous expressed biocatalysts. 354
NSAID biotransformations applying the identified microbial biocatalysts 355
To investigate the potential of the microbial biocatalysts further we increased the NSAID 356 substrate scope of the fungi strains to oxyfunctionalize naproxen (6), ibuprofen (8) and 357 mefenamic acid (12). In some cases, high titers and full conversion towards the investigatedmetabolite 6-o-desmethylnaproxen (7) with an isolated yield of over 99% using 1 g L -1 of 360 substrate (Scheme 2). In comparison the in vitro biotransformations with P450 BM3 361 variants and the strain A. niger showed much lower selectivity and isolated yield (Table 1) 362 (19, 20, 37) . 363
Furthermore, M. hiemalis almost completely hydroxylated 1 g L -1 ibuprofen (8) to the 364 metabolites 2-hydroxyibuprofen (9, 90%) 1-hydroxyibuprofen (10, 2%), and the double 365 hydroxylated secondary product 1,2-dihydroxyibuprofen (11, 8%) (Scheme 2). The highest 366 product titer so far was achieved by a P450 BM3 variant in vitro with 0.4 g L -1 of 367 2-hydroxyibuprofen (9) ( Table 1) (17, 20, 38) 
. Microorganisms such as 368
Trametes versicolor and Nigospora sphaerica or the P450s CYP2C9, CYP267A1 and B1 369 had significantly lower product yields (> 30 g L -1 ) (25, 39-41). Using the anthranilic acid 370 derivative mefenamic acid (12) as substrate, the highest activity was achieved by 371 B. bassiana with an isolated yield of 48% at 1 g L -1 substrate concentration (Scheme 2). 372
Next to the 3'-hydroxymethylmefenamic acid (13) as main product (68%), the product 373 3'-carboxymefenamic acid (14) was catalyzed. In humans, 12 is mainly converted to 13 by 374 CYP2C9 which undergoes further oxidation to the carboxy metabolite 14 (42). An evolved 375 P450 BM3 variant generated besides 3'-hydroxymethylmefenamic acid (13) the other 376 human P450 catalyzed metabolites 4'-and 5-hydroxymefenamic acid (20 and 21) which 377 are hydroxylated at the aromatic rings (18, 43) . In this case, in vitro product titers of 378 216 mg L -1 were below those obtained with B. bassiana (Table 1) . In degradation 379 experiments, the wild-type organism Phaenerochaete sordida (white-rot fungus) alsoproduced different mefenamic acid metabolites with significantly lower yields of less than 381 3 mg L -1 (26). 382
Overall, the filamentous fungi of the present study achieved high product titers in the 383 biotransformations with the NSAIDs. Applying a semi-preparative HPLC purification 384 method, all NSAID metabolites could be isolated in high yields and high purities. 385
Moreover, reproducible product titers were obtained at 50 mL or 400 mL scale exhibiting 386 the possibility to further increase the yields by improving the cultivation and 387 biotransformation procedure. One drawback of filamentous fungi as catalyst for 388 biotransformations is their mycelial growth. This particular cell shape minimizes the 389 possible surface to the medium and thus the mass transfer of substrate solubilized in the 390 medium and the cells. Especially cells located inside the mycelia may therefore be unable 391 to participate in biocatalysis, but against our expectation, the clump-forming organism 392
M. hiemalis has achieved the highest yields so far. 393
Compared to already published biotechnological processes the total process time with the 394 filamentous fungi of 4 days or 7 days for diclofenac (1), respectively, were in accordance 395 with most of the studies (Table 1 and 2). However, a simple cultivation and 396 biotransformation setup using fungi with less steps are main benefits, besides the achieved 397 high product yields. In detail, compared to P450-based reactions, less requirements on the 398 process were necessary since issues associated with an often complex P450 system like 399 biocatalyst expression, stability or cofactor dependency are negligible. 400
401
In conclusion, the results of the present work demonstrate the potential of microbial 402 biocatalysts for NSAID oxyfunctionalizations. Often, low activity, difficult handling, orhigh by-product formation are illustrated as criteria against the use of microorganisms (40) This study
a) The duration of the process includes cultivation of the main culture, expression (recombinant produced P450s) and subsequent biotransformation in days (d).
b) The product titer was calculated from isolated yields. substrate. The isolated yields after extraction and purification via semi-preparative HPLC
